{
  "sources": [
    {
      "title": "云野阁",
      "feedUrl": "https://marsperl.github.io/rss2.xml",
      "siteUrl": "https://yyg.js.cool/",
      "articles": [
        {
          "id": "https://yyg.js.cool/yyg/2eca17c7/",
          "author": null,
          "description": "博客加入Gitalk评论后，需要访问相应页面，才在存放评论的仓库创建Issues。本文通过脚本自动访问文章页面完成Gitalk自动创建评论Issues。脚本自attson/hexo-gitalk-init: Hexo gitalk 极简初始化脚本基础上修改而来（是在windows本地运行）。\n这是一个用于 Hexo 博客的 Gitalk 评论系统自动初始化脚本。它能自动扫描所有文章，识别出尚未创建评论 Issue 的页面，并通过模拟浏览器访问来触发 Gitalk 自动完成 Issue",
          "link": "https://yyg.js.cool/yyg/2eca17c7/",
          "publishedOn": "2025-10-08T14:06:07.000Z",
          "wordCount": 3172,
          "title": "Gitalk自动创建评论Issues",
          "imageUrl": "https://api.vvhan.com/api/wallpaper/views"
        },
        {
          "id": "https://marsperl.github.io/yyg/2eca17c7/",
          "author": null,
          "description": "博客加入Gitalk评论后，需要访问相应页面，才在存放评论的仓库创建Issues。本文通过脚本自动访问文章页面完成Gitalk自动创建评论Issues。脚本自attson/hexo-gitalk-init: Hexo gitalk 极简初始化脚本基础上修改而来（是在windows本地运行）。\n这是一个用于 Hexo 博客的 Gitalk 评论系统自动初始化脚本。它能自动扫描所有文章，识别出尚未创建评论 Issue",
          "link": "https://marsperl.github.io/yyg/2eca17c7/",
          "publishedOn": "2025-10-08T14:06:07.000Z",
          "wordCount": 4166,
          "title": "Gitalk自动创建评论Issues",
          "imageUrl": "https://picapi.pai.al/api/scenery.php"
        },
        {
          "id": "https://yyg.js.cool/yyg/986299a9/",
          "author": null,
          "description": "<a href=\"#网络\" class=\"headerlink\"",
          "link": "https://yyg.js.cool/yyg/986299a9/",
          "publishedOn": "2025-08-22T10:17:22.000Z",
          "wordCount": null,
          "title": "k8s知识梳理--进阶",
          "imageUrl": null
        },
        {
          "id": "https://marsperl.github.io/yyg/986299a9/",
          "author": null,
          "description": "<a href=\"#网络\" class=\"headerlink\"",
          "link": "https://marsperl.github.io/yyg/986299a9/",
          "publishedOn": "2025-08-22T10:17:22.000Z",
          "wordCount": 4569,
          "title": "k8s知识梳理--进阶",
          "imageUrl": "https://imgapi.cn/api.php?fl=fengjing&gs=images"
        },
        {
          "id": "https://yyg.js.cool/yyg/4789a872/",
          "author": null,
          "description": "前言\n在linux环境下，使用docker部署ollama+deepseek-r1:1.5b+open-webui，实现私有化部署DeepSeek。\n部署过程\n<a href=\"#安装docker\" class=\"headerlink\"",
          "link": "https://yyg.js.cool/yyg/4789a872/",
          "publishedOn": "2025-08-16T09:12:50.000Z",
          "wordCount": null,
          "title": "私有化部署DeepSeek",
          "imageUrl": null
        },
        {
          "id": "https://marsperl.github.io/yyg/4789a872/",
          "author": null,
          "description": "前言\n在linux环境下，使用docker部署ollama+deepseek-r1:1.5b+open-webui，实现私有化部署DeepSeek。\n部署过程\n<a href=\"#安装docker\"",
          "link": "https://marsperl.github.io/yyg/4789a872/",
          "publishedOn": "2025-08-16T09:12:50.000Z",
          "wordCount": null,
          "title": "私有化部署DeepSeek",
          "imageUrl": null
        }
      ]
    },
    {
      "title": "Hi, DIYgod",
      "feedUrl": "https://diygod.cc/feed/",
      "siteUrl": "https://diygod.cc",
      "articles": []
    },
    {
      "title": "whyes 的博客",
      "feedUrl": "http://whyes.org/feed.xml",
      "siteUrl": "http://whyes.org/",
      "articles": [
        {
          "id": "http://whyes.org/2025/abc-hcc-atezo-bev-tace-bclc-b",
          "author": null,
          "description": "一直以来，中期肝癌（BCLC B 期）被认为存在较大的异质性，从 2-3 枚肿瘤，其中一枚直径超过 3cm，到弥漫性肝癌，只要不伴有肉眼癌栓或远处转移，都属于中期肝癌。虽然在西方的指南中，中期肝癌的标准治疗是经肝动脉化疗栓塞（TACE），但...",
          "link": "http://whyes.org/2025/abc-hcc-atezo-bev-tace-bclc-b",
          "publishedOn": "2025-10-20T15:39:25.000Z",
          "wordCount": 180,
          "title": "ABC-HCC研究：系统治疗取代TACE，成为中期肝癌的标准治疗？ #ESMO25",
          "imageUrl": "https://i.typlog.com/whyes/8431633559_928745.jpg?x-oss-process=style/ss"
        },
        {
          "id": "http://whyes.org/2025/triplet-hcc-ipilimumab-atezo-bev",
          "author": null,
          "description": "",
          "link": "http://whyes.org/2025/triplet-hcc-ipilimumab-atezo-bev",
          "publishedOn": "2025-10-20T15:35:31.000Z",
          "wordCount": null,
          "title": "TRIPLET-HCC：小剂量伊匹木单抗未能给晚期肝癌一线靶免治疗增效 #ESMO25",
          "imageUrl": null
        },
        {
          "id": "http://whyes.org/2025/imbrave-152-tiragolumab-atezo-bev",
          "author": null,
          "description": "",
          "link": "http://whyes.org/2025/imbrave-152-tiragolumab-atezo-bev",
          "publishedOn": "2025-10-20T15:33:25.000Z",
          "wordCount": null,
          "title": "IMbrave152：TIGIT抗体未能给晚期肝癌的一线治疗增效 #ESMO25",
          "imageUrl": null
        },
        {
          "id": "http://whyes.org/2025/leap-012-hcc-tace-len-pembro-china",
          "author": null,
          "description": "在刚刚召开的 CSCO 年会上，LEAP-012 研究（中期为主的肝细胞癌：TACE+仑伐替尼+帕博利珠单抗 vs TACE+双安慰剂）公布了中国区患者的数据。主要借助中国区亚组的患者数据，这项联合治疗已经在国内获批上市，并且是同类方案中唯...",
          "link": "http://whyes.org/2025/leap-012-hcc-tace-len-pembro-china",
          "publishedOn": "2025-09-14T04:47:20.000Z",
          "wordCount": 178,
          "title": "LEAP-012 研究中国人群数据公布，OS 获益趋势明确 #CSCO25",
          "imageUrl": "https://i.typlog.com/whyes/8431633559_928745.jpg?x-oss-process=style/ss"
        }
      ]
    }
  ],
  "cliVersion": "1.15.1"
}